SGLT
Sodium-dependent glucose cotransporters
SGLTs (Sodium-dependent glucose cotransporters) are a family of glucose transporters and contribute to glucose reabsorption. The two most well-known members of SGLT family are SGLT1 and SGLT2, which are members of the SLC5A gene family. The two transporters are of primary importance for glucose homeostasis by absorbing glucose from the diet in the small intestine (via SGLT1) and by reabsorbing the filtered glucose in the tubular system of the kidney (primarily SGLT2; to smaller extent via SGLT1); the latter process returns glucose into the blood stream and prevents urinary glucose loss. SGLT1 and SGLT2 have been proposed as a novel therapeutic strategy for diabetes and cardiomyopathy.
SGLT Isoform Specific Products
All Product Categories
-
SGLT Related Products (97)
Related Products (97)
-
SGLT Isoform Comparison
-
HSK0935
0 ImagesCat. No.: HY-101782CAS No.: 1638851-44-1HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.
-
Sergliflozin etabonate
0 ImagesSynonyms: GW-869682XSergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.
-
Ertugliflozin (Standard)
0 ImagesSynonyms: PF-04971729 (Standard)Ertugliflozin (Standard) is the analytical standard of Ertugliflozin. This product is intended for research and analytical applications. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
-
SGLT1/2-IN-1
0 ImagesCat. No.: HY-138944CAS No.: 1673514-65-2SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .
-
Dapagliflozin-13C6-1
0 ImagesCat. No.: HY-10450S5Dapagliflozin-13C6-1 is 13C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
-
Rongliflozin
0 ImagesCat. No.: HY-153113CAS No.: 2648020-91-9Synonyms: DJT1116PGRongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM).
-
SGLT inhibitor-1
0 ImagesCat. No.: HY-112807CAS No.: 2247314-23-2SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively.
-
SGL5213
0 ImagesCat. No.: HY-114308CAS No.: 1240305-17-2SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment.
-
rel-Licogliflozin
0 ImagesCat. No.: HY-109092ACAS No.: 2730989-98-5Synonyms: rel-LIK066rel-Licogliflozin is a relative configuration of Licogliflozin (HY-109092). Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
-
Ertugliflozin-d9
0 ImagesCat. No.: HY-15461S1Synonyms: PF-04971729-d9Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
-
Atigliflozin
0 ImagesCat. No.: HY-14810CAS No.: 647834-15-9Synonyms: AVE-2268Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus.
-
WAY-123783
0 ImagesCat. No.: HY-114598CAS No.: 152595-59-0WAY-123783 is a potent, selective and orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor producing activity after metabolism. WAY-123783 can increase the excretion of sugar in urine and at the same time lower the blood sugar level in db/db mice (ED50 = 9.85 mg/kg). WAY-123783 can be used for the research of metabolic disease, such as diabetes.
-
Canagliflozin-d6
0 ImagesCat. No.: HY-10451S2Synonyms: JNJ 28431754-d6Canagliflozin-d6 is the deuterium labeled Canagliflozin. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
-
SGLT1/2-IN-2
0 ImagesCat. No.: HY-145357CAS No.: 2387812-73-7
-
Hypoglycemic agent 4
0 ImagesCat. No.: HY-180784Hypoglycemic agent 4 (Compound 5b) is a tetrahydroacridine derivative with orally active hypoglycemic activity. Hypoglycemic agent 4 has a good binding affinity for the key diabetic targets: DPP-IV, SGLT1, and GLUT2. Hypoglycemic agent 4 can inhibit glucose diffusion. Hypoglycemic agent 4 can reduce fasting blood sugar in Streptozotocin (HY-13753)-induced diabetic rats and its effect is comparable to Gliclazide (HY-B0753). Hypoglycemic agent 4 can be used for research of type 2 diabetes.
-
SGLT1/2-IN-8
0 ImagesCat. No.: HY-169821CAS No.: 2206679-16-3SGLT1/2-IN-8 (compound 8) is a potent and orally active SGLT1/2 dual inhibitor with IC50 values of 4 nM and 1 nM, respectively. SGLT1/2-IN-8 exhibits anti-hyperglycemic effects and can be utilized in relevant research.
-
Empagliflozin-d8
0 ImagesCat. No.: HY-166652SCAS No.: 2714418-84-3Empagliflozin-d8 is the deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
-
BI-44847
0 ImagesCat. No.: HY-117075CAS No.: 421592-30-5BI-44847 is a selective and orally active SGLT2 inhibitor. BI-44847 can increase UGE and decrease HbA1c levels. BI-44847 shows improvement in fasting and fed glucose levels. BI-44847 can be studied in research on type 2 diabetes mellitus (T2DM).
